1

Alteogen has disclosed the identity of the global pharmaceutical company that first licensed its subcutaneous (SC) formulation change platform technology, "ALT-B4."

Alteogen announced on June 18 that the initial license agreement counterparty for its Hybrozyme® platform-based ALT-B4 technology is the French pharmaceutical giant Sanofi.

In November 2019, the company disclosed that it had signed a non-exclusive technology transfer agreement for ALT-B4 worth a total of $1.373 billion with a top-tier global pharmaceutical company. However, the name of the partner had remained confidential until now in accordance with the terms of the contract.

ALT-B4 is a platform technology that facilitates the conversion of intravenous (IV) biologics into subcutaneous (SC) formulations. It has drawn significant attention from the global pharmaceutical industry because it reduces administration time and improves patient convenience.

Starting with this initial agreement, Alteogen has gone on to sign ALT-B4-related license deals with a total of eight global pharmaceutical companies to date, including Merck, AstraZeneca, GSK, Biogen, and Sandoz.

"By revealing our first partner, which had remained confidential, we have once again validated the technological value and commercial viability of the ALT-B4 platform," Jeon Tae-yeon, CEO of Alteogen, said. "As clinical development achievements accumulate moving forward, we expect global interest in our platform to expand even further." 

                                                                                                         Choi Jung-ah